Not suggesting at all that GTCB and CELG have anything in common from a product/platform perspective. Like I said; just waiting for validation that the platform GTCB has developed will be adopted by established pharm(s) to reduce unit production costs of existing or prospective drugs. I think this would be the catalyst that would move the stock price higher.
Market Data 
Markets 
AI
